Congress Asset Management CO Kymera Therapeutics, Inc. Transaction History

Congress Asset Management CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 11, 2024	BUY	$22.9 - $43.57 $12,205 - $23,222	533 Added 1.18%	45,836 $1.84 Million
Q4 2023 Mar 04, 2024	BUY	$10.97 - $26.84 $1,283 - $3,140	117 Added 0.26%	45,303 $1.15 Million
Q3 2023 Nov 01, 2023	BUY	$13.9 - $23.88 $847 - $1,456	61 Added 0.14%	45,186 $628,000
Q2 2023 Jul 27, 2023	BUY	$22.4 - $34.92 $12,454 - $19,415	556 Added 1.25%	45,125 $1.04 Million
Q1 2023 Apr 21, 2023	BUY	$24.84 - $38.75 $1.11 Million - $1.73 Million	44,569 New	44,569 $1.32 Million

184

64.4M

50.6K

81.7K

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.3B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

Get notified when there are updates to the investment portfolio of Congress Asset Management CO , based on Form 13F filings with the SEC.

Stay updated on Congress Asset Management CO with notifications on news.